RNS Number : 5485R
Evgen Pharma PLC
06 July 2022
 

Evgen Pharma plc

("Evgen" or the "Company)

Notice of AGM

Alderley Park, UK - 6 July 2022: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications, announces that its AGM will take place on 21 July 2022 at 2pm BST at its offices at Alderley Park, Congleton Road, Nether Alderley, Cheshire, SK10 4TG.

The Annual Report and Accounts for 2022 and AGM documents can be found on the company website at www.evgen.com.

Also on 21 July 2022, the Company will host a virtual presentation for investors via the InvestorMeet platform. Further details will be made available in due course.

-Ends-

Enquiries:

Evgen Pharma plc
Dr Huw Jones, CEO 
Richard Moulson, CFO 

+44 1625 466591

FinnCap (Nominated Advisor and Broker)
 Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane/Nigel Birks (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon

+44 207 457 2020
Evgen@Instinctif.com

 

Notes to Editors

About Evgen Pharma plc 

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. It will be entering the clinic in glioma/glioblastoma later in 2022.  In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology.

The Company commenced operations in January 2008 and has its headquarters and registered office at Alderley Park, Cheshire.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information, please visit: www.evgen.com 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAEAFXKEAAAEFA